MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Pharmaceutical Executive
July 1, 2005
Ken Dec
Direct to Consumer: Moving House The "House of Brands" model is a house of cards. The pharmaceutical industry should change, or risk losing trust forever. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2007
Porth & Sillup
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2009
Porth & Sillup
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2005
Zimmerman & Fay
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. mark for My Articles similar articles
Pharmaceutical Executive
July 30, 2007
Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2007
Stan Bernard
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. mark for My Articles similar articles
BusinessWeek
November 29, 2004
Catherine Arnst
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Thoughtleader: Peter Pitts. DrugWonks.com Here, the chief voice of a blog hosted by the non-profit Center for Medicine in the Public Interest urges pharma to continuously plug its positions and get politics out of science, and offers some perspective on important regulatory reforms facing the FDA. mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2005
Sarah Houlton
Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Porth & Sillup
Annual Press Audit: Front Page Pharma Newspapers in a study pool published more than twice as many front-page and editorial-page stories on the pharmaceutical industry than they did last year. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2013
Jill Wechsler
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2006
Ragnar Lofstedt
Back Page: The Post-Trust World People no longer put their faith in industry or regulators. What can we do about that? A good start would be understanding the human side of risk. mark for My Articles similar articles
The Motley Fool
February 28, 2011
Dan Dzombak
Rising Star Buy: Philip Morris International Why this tobacco king is worth buying. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2008
Patrick Clinton
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. mark for My Articles similar articles
BusinessWeek
October 18, 2004
Catherine Arnst
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma mark for My Articles similar articles
BusinessWeek
August 13, 2007
Arlene Weintraub
Putting Drug Ads Back In The Bottle Efforts to curb direct-to-consumer drug advertising are growing, but so far have met little success. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2012
Sillup & Porth
Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2005
Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2006
Sarah Houlton
Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China. mark for My Articles similar articles
The Motley Fool
July 2, 2010
Colleen Paulson
Government Snuffs Marlboro's Lights FDA's moves to control cigarette labeling and packaging take a bite. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Jeannette Park
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. mark for My Articles similar articles
The Motley Fool
May 26, 2009
Colleen Paulson
What's Your MO, Altria? Altria is actively supporting FDA regulation of cigarettes. Read on to see why. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2013
Sillup et al.
Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Glass & Poli
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2006
Patrick Clinton
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. mark for My Articles similar articles
The Motley Fool
November 10, 2009
Colleen Paulson
Altria's Not Tobacco's Only Altruist Reynolds American may purchase a quit-smoking company. mark for My Articles similar articles
The Motley Fool
September 9, 2004
Charly Travers
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Walter Armstrong
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. mark for My Articles similar articles
The Motley Fool
October 7, 2004
Brian Gorman
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. mark for My Articles similar articles
Chemistry World
May 2006
Bea Perks
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2008
Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2005
Patrick Clinton
PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Brad Miles
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. mark for My Articles similar articles
The Motley Fool
September 30, 2008
Brian Orelli
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. mark for My Articles similar articles
The Motley Fool
January 7, 2010
Colleen Paulson
Big Tobacco Is Back to Business Philip Morris USA touts "lower risk" smokeless tobacco. mark for My Articles similar articles
Bio-IT World
April 2007
Malorye Allison
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? mark for My Articles similar articles
The Motley Fool
July 23, 2009
Colleen Paulson
Maybe Altria Is Better Off Without Philip Morris Philip Morris earnings are hit by unfavorable currency exchange. mark for My Articles similar articles
BusinessWeek
February 28, 2005
Capell & Carey
A Drug Watchdog To Rival The FDA Europe's agency will soon have new powers. Will it take the lead on safety? mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Sarah Houlton
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice. mark for My Articles similar articles
The Motley Fool
February 22, 2005
Charly Travers
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. mark for My Articles similar articles
Chemistry World
July 10, 2012
Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies. mark for My Articles similar articles
The Motley Fool
June 15, 2010
Julie Clarenbach
Is This the Best Tobacco Buy? Who are the major tobacco retailers and how do they stack up to one another? mark for My Articles similar articles
Pharmaceutical Executive
July 3, 2007
Direct to Consumer: The Secret of My Success Pharmaceutical industry experts sound off on the methods behind an award-winning ad and how the next great direct-to-consumer campaign will come about. mark for My Articles similar articles
Reason
April 2001
Ronald Bailey
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? mark for My Articles similar articles
The Motley Fool
January 2, 2004
Selena Maranjian
Philip Morris Cuts Prices Will the cigarette maker's price cuts for wholesalers help boost profits? mark for My Articles similar articles
Bio-IT World
December 10, 2002
Malorye Branca
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. mark for My Articles similar articles
The Motley Fool
July 20, 2009
Colleen Paulson
A World of Growth for Philip Morris? Philip Morris continues its global expansion through acquisition. mark for My Articles similar articles